|
|
Volumn 96, Issue 2, 2004, Pages 96-97
|
|
For ovarian cancer, an optimal treatment remains to be found
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOCHEMICAL MARKER;
CARBOPLATIN;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
GEMCITABINE;
PACLITAXEL;
PROTEIN P53;
TOPOTECAN;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER MORTALITY;
CANCER RECURRENCE;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSSOVER PROCEDURE;
DRUG RESPONSE;
EUROPE;
FEMALE;
GENE EXPRESSION;
GENE EXPRESSION PROFILING;
HISTOPATHOLOGY;
HUMAN;
INTERMETHOD COMPARISON;
LAPAROSCOPY;
MATERIALS HANDLING;
MEDICAL DECISION MAKING;
MONOTHERAPY;
NOTE;
OUTCOMES RESEARCH;
OVARIECTOMY;
OVARY CANCER;
PATIENT REFERRAL;
PREDICTION;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN MICROARRAY;
SECOND LOOK SURGERY;
SYMPOSIUM;
TISSUE SECTION;
TREATMENT OUTCOME;
|
|
EID: 1042303678
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/96.2.96 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|